Bad Blood: A Case of Warm Autoimmune Hemolytic Anemia by Joshi, Amogh M, DO et al.
Lehigh Valley Health Network 
LVHN Scholarly Works 
Department of Medicine 
Bad Blood: A Case of Warm Autoimmune Hemolytic Anemia 
Amogh M. Joshi DO 
Lehigh Valley Health Network, Amogh.Joshi@lvhn.org 
Kevin J. Hess DO 
Lehigh Valley Health Network, Kevin.Hess@lvhn.org 
Zeeshan Ali MD 
Lehigh Valley Health Network, Zeeshan.Ali@lvhn.org 
Nicholas Lamparella DO 
Lehigh Valley Health Network, Nicholas.Lamparella@lvhn.org 
Follow this and additional works at: https://scholarlyworks.lvhn.org/medicine 
 Part of the Hematology Commons, and the Internal Medicine Commons 
Published In/Presented At 
Joshi, A., Hess, K., Ali, Z., & Lamparella, N. (2020, September). Bad Blood: A Case of Warm Autoimmune 
Hemolytic Anemia. Poster Presented at: Pennsylvania Society of Oncology and Hematology Annual 
Meeting, Virtual. 
This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion 
in LVHN Scholarly Works by an authorized administrator. For more information, please contact 
LibraryServices@lvhn.org. 
© 2020 Lehigh Valley Health Network
LVHN.org
Rapid stabilization and early 
initiation of corticosteroids  
remain the cornerstone  
of AIHA management.  
Close follow-up with thorough 
diagnostic evaluation and 
appropriate therapeutic  
escalation is critical to  
maintaining safe outcomes.
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INTRODUCTION
Autoimmune Hemolytic Anemia (AIHA) is a rare autoimmune phenomenon where auto antibodies target host 
erythrocytes for destruction. AIHAs can be classified as idiopathic, warm agglutinin or cold agglutinin mediated. 
Initial clinical presentation can vary from mild symptomology to fulminant disease. Clinical presentation varies 
depending on the extent of anemia and the level of physiologic compensation. We describe the case of a 
patient presenting with symptomatic warm AIHA.
CASE REPORT
A 31 year old female without significant past medical history presented with new onset dyspnea, palpitations 
and lightheadedness. Physical examination demonstrated, no active or occult bleeding, conjunctival pallor and 
scleral and sublingual icterus. Serum chemistries demonstrated a Total Bilirubin of 5.1 mg/dL, Haptoglobin of  
4 mg/dL and Lactate Dehydrogenase of 533 U/L. Complete Blood Count demonstrated a Hgb of 5.8 g/dL, Hct 
of 17%, MCV of 122 fL and Reticulocytes of 19.1%. Direct Anti-Globulin Testing was positive for 3+ C3D, 2+ 
Anti-IgG and warm antibodies. Peripheral smear demonstrated marked polychromasia and basophilic stippling. 
Computed tomography of the abdomen and pelvis with intravenous contrast demonstrated hepatosplenomegaly, 
but no masses or lymphadenopathy. The patient received two transfusions of packed red blood cells and  
was promptly started on high dose corticosteroids with good clinical response and subsequent stabilization  
of her hemoglobin.
DISCUSSION
This case highlights that while AIHA is a rare cause of anemia, clinicians should maintain a high degree of 
suspicion for this disease in patients with unexplained severe anemia. AIHA can be subdivided into primary 
(idiopathic) AIHA and secondary AIHA which has been associated with lymphoma, autoimmune disease, 
medications or infections. Etiologic determination guides subsequent intervention, as secondary causes must be 
evaluated and concomitantly treated for sustained therapeutic response. Initial stabilization of the patient is of 
paramount importance. Blood transfusion should not be delayed due to matching difficulties and transfusion 
with the “least incompatible” blood products should be started as appropriate. First-line therapy consists of high 
dose corticosteroids dosed at 1mg/kg until the hemoglobin concentration exceeds 10g/dL, followed by a 
subsequent slow taper over the course of three to four months. Many patients require either maintenance dose 
corticosteroids or initiation of second line therapies, such as splenectomy or the anti cd20 monocolonal 
antibody, Rituximab. Refractory disease is classically treated with cytotoxic agents such as, cyclophosphamide. 
Rapid stabilization and early initiation of corticosteroids remains the cornerstone of initial management and 
close follow-up with thorough diagnostic evaluation and appropriate therapeutic escalation is critical to 
maintaining safe outcomes.
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